MAPT and Alzheimer disease: Animal and human studies demonstrate that in the prodromal and preclinical stages of AD, sleep disturbances induce higher beta-amyloid impacts in the brain [4–7], enhance tau accumulation in the interstitial fluid (ISF) and cerebrospinal fluid (CSF) [4], increase the risk of clinical diagnosis of AD [8], and accelerate cognitive decline [2, 8–14].